A safety and efficacy study of CTX001 in transfusion-dependent patients with ß-Thalassemia

Trial Profile

A safety and efficacy study of CTX001 in transfusion-dependent patients with ß-Thalassemia

Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs CTX 001 (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use
  • Sponsors CRISPR Therapeutics
  • Most Recent Events

    • 07 Dec 2017 According to a CRISPR Therapeutics media release, the company has submitted a Clinical Trial Application (CTA) to conduct this trial.
    • 15 Nov 2017 New trial record
    • 08 Nov 2017 According to a CRISPR Therapeutics media release, the company will filed CTA package filed by year-end 2017 to begin this trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top